Re: What's the deal with Zenith?
in response to
by
posted on
Jun 22, 2023 03:19PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
tada - I didn't forget ZEL royalties. I believe DM opened the conversation by saying Zenith owned RVX Royalty Preferred Shares so it would only be a portion of those, not any royalties in ZEL. They are two totally different things and one is RVX royalties and one is ZEL royalties. He totally led me to believe that he was talking RVX royalties.
I am not sure it is better to leave RVX floundering as the RPS's in RVX are pretty much worthless as long as RVX flounders and if it fails, they become totally worthless. This plan might create some value for them.
We definitely need details on the mechanics but I doubt we will get much there unless we actually get interest and a deal for them.